American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Chemotherapy Sensitivity and Resistance Assays

Burstein, Harold J.; Mangu, Pamela B.; Somerfield, Mark R.; Schrag, Deborah; Samson, David J; Holt, L.; Zelman, Debra; Ajani, Jaffer A.

doi:10.1200/jco.2011.36.0354

Cited by 128 publications

(134 citation statements)

References 6 publications

Supporting

Mentioning

131

Contrasting

Unclassified

Order By: Relevance

“…Numerous attempts have been made to develop a personalized in vitro platform to predict treatment response in individual patients, but no method has presently gained clinical acceptance (1). Cell lines are not readily established for every individual patient, and although a higher take rate and early signs of predictive value have been reported for patient-derived xenograft models, the 6-8 mo required to gain sufficient material may prohibit its development as a clinical decision-making tool (2).…”

mentioning

confidence: 99%

Preserved genetic diversity in organoids cultured from biopsies of human colorectal cancer metastases

Weeber

Wetering

Hoogstraat

et al. 2015

Proc. Natl. Acad. Sci. U.S.A.

373

345

View full text Add to dashboard Cite

Tumor organoids are 3D cultures of cancer cells. They can be derived from the tumor of each individual patient, thereby providing an attractive ex vivo assay to tailor treatment. Using patient-derived tumor organoids for this purpose requires that organoids derived from biopsies maintain the genetic diversity of the in vivo tumor. In this study tumor biopsies were obtained from 14 patients with metastatic colorectal cancer (i) to test the feasibility of organoid culture from metastatic biopsy specimens and (ii) to compare the genetic diversity of patient-derived tumor organoids and the original tumor biopsy. Genetic analysis was performed using SOLiD sequencing for 1,977 cancer-relevant genes. Copy number profiles were generated from sequencing data using CopywriteR. Here we demonstrate that organoid cultures can be established from tumor biopsies of patients with metastatic colorectal cancer with a success rate of 71%. Genetic analysis showed that organoids reflect the metastasis from which they were derived. Ninety percent of somatic mutations were shared between organoids and biopsies from the same patient, and the DNA copy number profiles of organoids and the corresponding original tumor show a correlation of 0.89. Most importantly, none of the mutations that were found exclusively in either the tumor or organoid culture are in driver genes or genes amenable for drug targeting. These findings support further exploration of patient-derived organoids as an ex vivo platform to personalize anticancer treatment.biopsy-derived tumor organoids | colorectal cancer | DNA sequencing | copy number analysis | personalized medicine

show abstract

mentioning

confidence: 99%

Preserved genetic diversity in organoids cultured from biopsies of human colorectal cancer metastases

Weeber

Wetering

Hoogstraat

et al. 2015

Proc. Natl. Acad. Sci. U.S.A.

373

345

View full text Add to dashboard Cite

show abstract

“…Нередко наблюдения по сопоставлению результатов in vitro и ex vivo были малочисленны, а если и име-ли представительную выборку, то не были аккуратно спланированы. Порой в них отсутствуют сведения о длительности безрецидивного и общего выжива-ния пациентов, его качестве, неблагоприятных по-бочных реакциях, а также не фигурируют «слепые» сравниваемые группы [15,37]. Отсюда проистекает известная сдержанность в общей оценке проблемы.…”

Section: результаты и обсуждениеunclassified

“…Отсюда проистекает известная сдержанность в общей оценке проблемы. В 2012 г. появился обширный системный обзор [15] членов рабочей группы Американской ассоциации клинической онкологии (American Society of Clinical Oncology -ASCO), посвященный критическому ана-лизу преимуществ, директированных существую-щими методами определения in vitro терапии перед групповой. Резюмирующая часть содержит форму-лировку: «использование химиотерапевтических пре-паратов для индивидуализации терапии пациентов не рекомендуется объективной реальностью» пока не будет проверено медицинской практикой.…”

Section: результаты и обсуждениеunclassified

Developing options for method of assessing the sensitivity of cells intracranial neoplasms to chemotherapeutics in vitro

Chernov¹,

Калюнов²,

Конопля³

2015

Zlokač. opuholi

View full text Add to dashboard Cite

“…Clinicians and investigators frequently compare the MiCK assay with previously published chemotherapy sensitivity and resistance assays (12)(13)(14). However, the MiCK assay is a novel analysis that differs from such previous technologies in substantial ways.…”

Section: Comparison Of the Mick Assay With Chemotherapy Sensitivity Amentioning

confidence: 99%

The Microculture-Kinetic (MiCK) Assay: The Role of a Drug-Induced Apoptosis Assay in Drug Development and Clinical Care

et al. 2012

View full text Add to dashboard Cite

A drug-induced apoptosis assay, termed the microculture-kinetic (MiCK) assay, has been developed. Blinded clinical trials have shown higher response rates and longer survival in groups of patients with acute myelocytic leukemia and epithelial ovarian cancer who have been treated with drugs that show high apoptosis in the MiCK assay. Unblinded clinical trials in multiple tumor types have shown that the assay will be used frequently by clinicians to determine treatment, and when used, results in higher response rates, longer times to relapse, and longer survivals. Model economic analyses suggest possible cost savings in clinical use based on increased generic drug use and single-agent substitution for combination therapies. Two initial studies with drugs in development are promising. The assay may help reduce costs and speed time to drug approval. Correlative studies with molecular biomarkers are planned. This assay may have a role both in personalized clinical therapy and in more efficient drug development. Cancer Res; 72(16);

show abstract

American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Chemotherapy Sensitivity and Resistance Assays

Cited by 128 publications

References 6 publications

Preserved genetic diversity in organoids cultured from biopsies of human colorectal cancer metastases

Preserved genetic diversity in organoids cultured from biopsies of human colorectal cancer metastases

Developing options for method of assessing the sensitivity of cells intracranial neoplasms to chemotherapeutics in vitro

The Microculture-Kinetic (MiCK) Assay: The Role of a Drug-Induced Apoptosis Assay in Drug Development and Clinical Care

Contact Info

Product

Resources

About